Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $14 from $11 and keeps a Buy rating on the shares ...
Vanda Pharmaceuticals received FDA approval for Nereus for motion sickness, and its shares offer upside potential into 2026 ...
As of Wednesday, December 31, Vanda Pharmaceuticals Inc.’s VNDA share price has surged by 34.23%, which has investors ...
Drugmakers will increase prices on 350 drugs, despite pressure from Trump. Vanda Pharmaceuticals' motion sickness drug is FDA ...
Vanda Pharmaceuticals' shares surged in after-hours trading following FDA approval of NEREUS for preventing motion-induced ...
The FDA decision was based on results from three late-stage clinical studies, including two Phase 3 trials conducted in ...
Pharmaceutical companies in the U.S. plan to increase prices on 350 medications despite political pressure. Vanda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback